Hereditary amyloidosis describes a group of inherited disorders in which an abnormal protein called amyloid accumulates in multiple organ tissues, disrupting normal structure and function (Orphanet; GARD). The condition represents a broad umbrella encompassing several recognized subtypes, including Finnish-type amyloidosis, cerebral amyloid angiopathy, familial amyloid neuropathy, and familial visceral amyloidosis, each with distinct genetic and clinical characteristics.

Clinical manifestations depend on the specific subtype and the organ systems affected by amyloid deposition. No consolidated phenotype data are available in this packet at the umbrella level; symptom profiles are more precisely characterized within individual subtype entries.

Hereditary amyloidosis arises from inherited genetic variants that cause abnormal protein misfolding and aggregation into amyloid fibrils within tissues. The specific causative genetic mechanisms vary across the recognized subtypes of this umbrella category. No specific causative genes are documented in this packet at the umbrella level.

Diagnosis of amyloidosis is typically established through tissue biopsy demonstrating amyloid deposits, which stain positive with Congo red and exhibit characteristic apple-green birefringence under polarized light microscopy. Genetic testing is used to identify specific inherited subtypes and confirm hereditary forms. No diagnostic criteria specific to this umbrella entry are documented in the current packet.

No approved treatments are documented in this packet at the hereditary amyloidosis umbrella level. Management strategies relevant to individual subtypes are detailed within those respective disease entries.

Prognosis in hereditary amyloidosis varies by subtype and by which organ systems are affected by amyloid deposition. No consolidated natural history or outcome data are available in this packet at the umbrella level.

Active clinical investigation into hereditary amyloidosis and its subtypes is ongoing, with trial records spanning drug therapy and biologic interventions, and contributions from sponsors including Alnylam Pharmaceuticals and Eidos Therapeutics (ClinicalTrials.gov). Published scientific literature includes over 250 classified articles, with reviews, biomarker studies, and gene therapy research represented across the hereditary amyloidosis spectrum.